Author:
Lin Yeong-Liang,Chan Keith
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug guides,Pharmacology (nursing)
Reference65 articles.
1. Haverkamp W. Breithardt G, Camm AJ. et al. The potential for QT prolongation and proarrhythmia by non-arrhythmic drugs: clinical and regulatory implication: report on a policy conference of the European Society of Cardiology. Eur Heart J. 2000;21:1216-1231.
2. Anderson ME. Al Khalib SM. Roden DM. et al. Cardiac repolarization: current knowledge, critical gaps and new approaches to drug development and patient management. Am Heart J. 2002;144:769-781.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antianhythmic Drugs. Geneva, Switzerland: International Conference on Harmonisation: 2005.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Geneva. Switzerland: International Conference on Harmonisation, 2005.
5. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmetic drugs that prolong the QT interval or induce torsade de pointes. Drug Safety. 2002;25:263–286.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献